Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
Filgotinib could be the safest Jak inhibitor yet, but Galapagos will need to make the most of this as it squares up to Abbvie.
Rivipansel needs to help sickle cell patients leave hospital sooner and BCX7353 faces established hereditary angioedema agents.
Notable US regulatory decisions due in April feature a major pipeline hope from Abbvie, a non-opioid pain medication from Heron and Glaxo’s two-pill HIV regimen.
The long overdue readout of a pivotal birch pollen allergy vaccine trial draws a blank for the beleaguered UK company.
Sanofi might only get the US go-ahead for its dengue vaccine Dengvaxia in a narrow population, leaving the door open for its rival Takeda.
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
DBV plans to refile Viaskin Peanut in the third quarter, but things look all but smooth.